TY  - JOUR
PY  - 2020//
TI  - Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: a post hoc analysis
JO  - International journal of geriatric psychiatry
A1  - Ballard, Clive G.
A1  - Coate, Bruce
A1  - Abler, Victor
A1  - Stankovic, Serge
A1  - Foff, Erin
SP  - ePub
EP  - ePub
VL  - ePub
IS  - ePub
N2  - OBJECTIVES: Patients with Alzheimer's disease psychosis (ADP) commonly experience concomitant agitation and aggression. We investigated whether a reduction in ADP following pimavanserin treatment conferred a reduction in associated agitation and aggression.     METHODS: ACP-103-019 was a 12-week, randomized, double-blind, placebo-controlled study that evaluated the efficacy of pimavanserin (34 mg) in reducing psychotic symptoms in patients with ADP. The primary endpoint was change from baseline in Neuropsychiatric Inventory-Nursing Home Version-Psychosis Score (NPI-NH-PS) at week six. A post hoc analysis examined whether there was a greater reduction in agitation and aggression (NPI-NH domain C [agitation/aggression] and Cohen-Mansfield Agitation Inventory-Short Form [CMAI-SF]) in pimavanserin-treated patients who experienced a reduction of hallucinations and delusions (psychosis responders defined as ≥50% reduction from baseline in NPI-NH-PS, week six) when compared with those who did not (nonresponders).     RESULTS: Pimavanserin-treated patients with ≥50% response in psychotic symptoms (n = 44) showed a greater improvement in agitation and aggression symptoms on the NPI-NH domain C (week six, least squares mean [LSM] difference = -3.64, t = -4.69, P < 0.0001) and the CMAI-SF (week six, LSM difference = -3.71, t = -2.01, P = 0.0483) than nonresponders (n = 32). Differences between psychosis responders and nonresponders were also observed in patients with more severe agitation and aggression at baseline on the NPI-NH domain C (responders, n = 26; nonresponders, n = 13; week six, LSM difference = -3.03, t = -2.44, P = 0.019).     CONCLUSIONS: Patients with ADP who show improvement in psychotic symptoms following pimavanserin treatment also experience an improvement in concomitant agitation and aggression. This article is protected by copyright. All rights reserved.<p />  <p>Language: en</p>
LA  - en
SN  - 0885-6230
UR  - http://dx.doi.org/10.1002/gps.5381
ID  - ref1
ER  -